A decade after the very first psoriasis patient was treated with Cosentyx (secukinumab), Novartis is rolling out a fresh set of data underscoring just how durable the response rates are among patients taking the therapy.
In a 5-year followup, researchers for Novartis $NVS say that skin clearance rates have remained virtually unchanged for this IL-17A blockbuster. Looking at PASI 75/90/100, the one-year scores were 89%, 69% and 44%. At year five the PASI rates lined up at 89%, 66% and 41%.
In other words, when this drug works, it continues to work remarkably consistently for as far out as the company has been able to track. And this new data follows a similarly positive three-year followup for this drug in ankylosing spondylitis.
That’s a big deal for Novartis, which was out front in the new wave of psoriasis drugs that’s been hitting the market. In Q2 the pharma giant reported close to $500 million in sales as CEO Joe Jimenez crowed that “we see $2 billion of full year sales within reach.”
Novartis though, has a growing group of rivals nipping at its heels. With Eli Lilly fielding Taltz, Valeant pushing Siliq and J&J bagging a key FDA win in July for its blockbuster contender guselkumab, Novartis wants to do everything it can to highlight the positives on this drug, which launched a couple of years ago.
“Cosentyx is the first and only IL-17A inhibitor approved for psoriasis, psoriatic arthritis and ankylosing spondylitis and has been prescribed to more than 100,000 patients since launch,” says Vas Narasimhan, Novartis’ development chief and the designated heir to the throne, who will be moving to the helm in February.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.Free Subscription